Introduction

Injectable medicines are not what they used to be in the management of diabetes, with new formulations and devices providing more convenient and appealing ways to manage medication administration.

Over the past five years a number of new injectable medicines have been registered and PBS subsidised in Australia for the management of type 2 diabetes. They include a new injectable glucagonlike peptide-1 (GLP-1) analogue, an ultra-long-acting insulin, a newly formulated long-acting exenatide, and a higher concentration insulin glargine. The practical advantages and disadvantages of these injectable therapies must be considered in conjunction with the evidence for their impact on both surrogate and longer term outcomes.

Learning objectives

After successful completion of this CPD activity, pharmacists should be able to:

  • Summarise the new injectable therapies in type 2 diabetes
  • Discuss the advantages and disadvantages of injectable therapies in type 2 diabetes
  • Explain the differences within the classes of glucagon-like peptide (GLP-1) analogues and newer insulin formulations.

Competencies (2016): 1.1, 1.4, 1.5, 1.6, 3.5

Already read the CPD in the journal? Scroll to the bottom to SUBMIT ANSWERS.

THIS IS A CPD ARTICLE. YOU NEED TO BE A PSA MEMBER AND LOGGED IN TO READ MORE.